COMMUNIQUÉS West-GlobeNewswire

F2G Announces Posters Accepted for Presentation at Upcoming Medical Meetings
01/09/2026
MANCHESTER, United Kingdom, Sept. 01, 2026 (GLOBE NEWSWIRE) -- F2G Ltd., today announced abstracts accepted for presentation at the MSGERC 2026 Biennial Meeting in September and ISPOR Europe 2026 in November. Details of [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/09/2026
CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved [...]
Ardelyx to Participate in Upcoming Investor Conferences
01/09/2026
WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative [...]
BridgeBio to Participate in September Investor Conferences
01/09/2026
PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for [...]
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
01/09/2026
– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high) support [...]
Vera Therapeutics to Participate at Upcoming Investor Conferences
01/09/2026
BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will present and participate in [...]
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
01/09/2026
Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen [...]
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
01/09/2026
ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have [...]
Applied Biologics Activates First Clinical Site in Phase 3 BIOxHEAL™ Trial
01/09/2026
Milestone marks transition to active site-level execution with patient screening and enrollment expected to begin shortly SCOTTSDALE, Ariz., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical [...]
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
01/09/2026
GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and [...]
CytomX Therapeutics to Present at Upcoming September Investor Conferences
01/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will [...]
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
01/09/2026
EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative [...]
Resolution Therapeutics partners with the Blood Centers of America, Inc. to support broad patient access to its experimental Regenerative Macrophage Therapy in the U.S.
01/09/2026
Partnership will support Resolution’s pivotal clinical program in 2027, as well as future commercial preparedness for RTX001, its lead asset in patients with end-stage liver disease (ESLD) Primary goal is to ensure [...]
ENA Respiratory Awarded Biointelect Venturer Funding to Support New Study in Asthma Patients of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
01/09/2026
MELBOURNE, Australia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral [...]
Transactions in connection with share buy-back program
01/09/2026
Company announcement no. 33 - 26 01 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
01/09/2026
Ingelheim, Germany, and Bracknell, United Kingdom SCOVELLA® is the first therapy specifically developed and approved for the treatment of hyperinsulinemia in insulin-dysregulated horses and ponies 1 , targeting the key [...]
The Insides Company franchit une nouvelle étape vers le remboursement de son dispositif médical The Insides System® en France
01/09/2026
La Haute Autorité de Santé rend un avis favorable à l’inscription de The Insides System® sur la Liste des Produits et Prestations Remboursables (LPPR), franchissant une étape décisive vers une prise en charge pérenne [...]
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
01/09/2026
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule [...]
argenx to Present at Upcoming Investor Conferences
01/09/2026
September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor [...]

Pages